Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Apollo Global Management Ord Shs — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.84 (market cap $5.07B), while Apollo Global Management Ord Shs trades at $140.47 (market cap $82.84B). The key difference: Apollo Global Management Ord Shs is far larger — about 16.3× ACADIA Pharmaceuticals Inc.'s market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | APO | |
|---|---|---|
Market Cap | $5.07B | $82.84B |
Sector | Health | Financials |
52-Week High | $29.41 | $152.70 |
52-Week Low | $20.06 | $100.30 |
Enterprise Value | $4.19B | -$168.65B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Apollo Global Management (APO) trades at $132.02, up 3.59% in 24 hours, with strong technical momentum as it approaches resistance near $134. The company reported mixed Q2 2026 earnings, missing EPS estimates but achieving record fee-related earnings of $785 million (Seeking Alpha, August 4, 2026). Fundamentals show robust revenue growth, with 2025 revenue at $32.05 billion, though net income margins have declined to 5.22% from prior peaks.
Outlook remains positive with an 82% analyst buy rating and a $151.50 price target, but risks include high P/E of 49.92 and exposure to private credit market volatility. Recent news highlights strategic AI infrastructure deals, such as a $2.6 billion partnership with Yankee Global Enterprises (Business Wire, August 11, 2026), supporting long-term growth amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
